India Pharma Outlook Team | Thursday, 09 July 2026
Wegovy is making a strong comeback in India's fast-growing weight loss drug market as generic weight loss drugs begin to lose momentum.
Just months after generic semaglutide entered the market with high expectations, fresh sales data shows the growth of copycat versions has slowed sharply.
The shift has helped Novo Nordisk regain ground with its branded products, while doctors say many patients continue to prefer trusted brands over cheaper alternatives.
The latest market trends suggest the India GLP-1 market is becoming more competitive than expected. Instead of taking business away from branded medicines, dozens of generic companies are now competing with each other, making it harder for any single brand to stand out.
Sales growth for generic semaglutide dropped to 4.4% in June, a sharp decline from 15.3% in May, according to market data cited by The Economic Times. While generic medicines remain in demand, the rapid growth seen after their launch has started to cool.
At the same time, Ozempic and Wegovy continued to post steady month-on-month growth. Novo Nordisk's partner brands, including Poviztra and Extensior, also maintained healthy sales.
Industry experts say one major reason is pricing. After Novo Nordisk reduced Wegovy prices by up to 48%, the gap between branded medicines and generic alternatives narrowed significantly. With only a small difference in cost, many doctors believe patients are choosing products backed by years of clinical evidence.
Also Read: Choosing the Right CDMO in India: A 2026 Compliance Guide
Endocrinologists quoted in the report said many patients already recognize the Ozempic name and feel more confident using an established medicine. Doctors also said they are more comfortable prescribing a product with a proven safety and effectiveness record, especially when the price difference is no longer substantial.
Another challenge for generic manufacturers is the crowded market. Around 31 generic semaglutide brands are currently available in India. Rather than competing mainly with Novo Nordisk, these companies are increasingly competing against one another.
Key reasons behind Wegovy's comeback include:
India's weight loss drug market remains one of the fastest-growing pharmaceutical segments, but the latest numbers show that low prices alone may not guarantee success.
Competition is also increasing from other global players. Eli Lilly's Mounjaro continued to perform strongly in India and remained the highest-selling GLP-1 medicine by value, although its unit sales recorded a slight decline in June.
The latest trend marks a change from earlier expectations that generic semaglutide would quickly dominate the market after patent expiry. Instead, Novo Nordisk's aggressive pricing strategy and strong brand recognition have helped it hold on to a significant share of the market.
As more companies enter the GLP-1 space, experts believe competition will increasingly depend on pricing, doctor confidence, patient trust, and long-term clinical data rather than cost alone. The coming months will determine whether generic manufacturers can regain momentum or if branded drugs continue to lead India's rapidly expanding weight loss market.
